OBD vs. ONC, IXI, TCF, SNG, EVG, MTFB, ROQ, DEST, BSFA, and RENE
Should you be buying Oxford BioDynamics stock or one of its competitors? The main competitors of Oxford BioDynamics include Oncimmune (ONC), IXICO (IXI), Theracryf (TCF), Synairgen (SNG), Evgen Pharma (EVG), Motif Bio (MTFB), Roquefort Therapeutics (ROQ), Destiny Pharma (DEST), BSF Enterprise (BSFA), and ReNeuron Group (RENE). These companies are all part of the "biotechnology" industry.
Oxford BioDynamics vs.
Oxford BioDynamics (LON:OBD) and Oncimmune (LON:ONC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.
Oxford BioDynamics received 36 more outperform votes than Oncimmune when rated by MarketBeat users. Likewise, 60.82% of users gave Oxford BioDynamics an outperform vote while only 59.13% of users gave Oncimmune an outperform vote.
In the previous week, Oxford BioDynamics and Oxford BioDynamics both had 1 articles in the media. Oxford BioDynamics' average media sentiment score of 0.00 beat Oncimmune's score of -0.45 indicating that Oxford BioDynamics is being referred to more favorably in the media.
Oxford BioDynamics has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Oncimmune has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.
Oncimmune has a net margin of 581.63% compared to Oxford BioDynamics' net margin of -1,800.32%. Oxford BioDynamics' return on equity of -289.38% beat Oncimmune's return on equity.
44.3% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 25.0% of Oncimmune shares are owned by institutional investors. 16.8% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 31.0% of Oncimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Oncimmune has lower revenue, but higher earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Oncimmune, indicating that it is currently the more affordable of the two stocks.
Summary
Oxford BioDynamics and Oncimmune tied by winning 7 of the 14 factors compared between the two stocks.
Get Oxford BioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford BioDynamics Competitors List
Related Companies and Tools
This page (LON:OBD) was last updated on 2/22/2025 by MarketBeat.com Staff
